Insider Selling: Mark Christopher Capone Unloads 87,500 Shares of Myriad Genetics Stock (MYGN)
Myriad Genetics (NASDAQ:MYGN) Insider Mark Christopher Capone unloaded 87,500 shares of the company’s stock on the open market in a transaction dated Monday, February 10th. The stock was sold at an average price of $32.07, for a total value of $2,806,125.00. Following the completion of the sale, the insider now directly owns 48,268 shares in the company, valued at approximately $1,547,955. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Myriad Genetics (NASDAQ:MYGN) traded down 0.68% on Monday, hitting $32.01. The stock had a trading volume of 1,655,053 shares. Myriad Genetics has a 52 week low of $20.02 and a 52 week high of $38.27. The stock’s 50-day moving average is $25.15 and its 200-day moving average is $26.1. The company has a market cap of $2.403 billion and a P/E ratio of 13.92.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, February 4th. The company reported $0.66 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.46 by $0.20. The company had revenue of $204.06 million for the quarter, compared to the consensus estimate of $176.02 million. During the same quarter last year, the company posted $0.42 earnings per share. Myriad Genetics’s revenue was up 36.9% compared to the same quarter last year. Analysts expect that Myriad Genetics will post $2.17 EPS for the current fiscal year.
A number of research firms have recently commented on MYGN. Analysts at Credit Suisse upgraded shares of Myriad Genetics from an “underperform” rating to a “neutral” rating in a research note to investors on Friday. They now have a $29.00 price target on the stock. Separately, analysts at Ladenburg Thalmann downgraded shares of Myriad Genetics from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, February 5th. Finally, analysts at JMP Securities upgraded shares of Myriad Genetics from an “underperform” rating to a “market perform” rating in a research note to investors on Wednesday, February 5th. They now have a $30.80 price target on the stock. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company. Myriad Genetics presently has a consensus rating of “Hold” and a consensus price target of $27.77.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.